- Home
- CIEN vs EXEL Comparison
CIEN vs EXEL Comparison
Compare CIEN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIEN
- EXEL
- Stock Information
- Founded
- CIEN 1992
- EXEL 1994
- Country
- CIEN United States
- EXEL United States
- Employees
- CIEN N/A
- EXEL N/A
- Industry
- CIEN Telecommunications Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIEN Utilities
- EXEL Health Care
- Exchange
- CIEN Nasdaq
- EXEL Nasdaq
- Market Cap
- CIEN 12.8B
- EXEL 10.4B
- IPO Year
- CIEN 1997
- EXEL 2000
- Fundamental
- Price
- CIEN $131.23
- EXEL $39.15
- Analyst Decision
- CIEN Buy
- EXEL Buy
- Analyst Count
- CIEN 15
- EXEL 21
- Target Price
- CIEN $113.96
- EXEL $43.65
- AVG Volume (30 Days)
- CIEN 2.9M
- EXEL 2.3M
- Earning Date
- CIEN 09-04-2025
- EXEL 10-28-2025
- Dividend Yield
- CIEN N/A
- EXEL N/A
- EPS Growth
- CIEN 3.32
- EXEL 81.76
- EPS
- CIEN 0.98
- EXEL 2.08
- Revenue
- CIEN $4,541,635,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- CIEN $16.41
- EXEL $9.24
- Revenue Next Year
- CIEN $10.12
- EXEL $13.04
- P/E Ratio
- CIEN $134.01
- EXEL $18.85
- Revenue Growth
- CIEN 12.97
- EXEL 10.73
- 52 Week Low
- CIEN $49.21
- EXEL $25.17
- 52 Week High
- CIEN $134.31
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CIEN 82.28
- EXEL 54.56
- Support Level
- CIEN $90.00
- EXEL $36.78
- Resistance Level
- CIEN $134.31
- EXEL $37.93
- Average True Range (ATR)
- CIEN 4.27
- EXEL 0.94
- MACD
- CIEN 3.68
- EXEL 0.30
- Stochastic Oscillator
- CIEN 93.14
- EXEL 96.21
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.